CD68 staining correlates with the size of residual mass but not with survival in classical Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 56, Issue 5, 2015, Pages 1315-1319

  Agur, Ariel ^a   Amir, Gail ^a   Paltiel, Ora ^a   Klein, Martine ^a   Dann, Eldad J ^b   Goldschmidt, Hanoch ^a   Goldschmidt, Neta ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Clinical Research Institute at Rambam Healthcare Campus   (Israel)

Author keywords

CD68; Hodgkin; Macrophages; Prognosis; Residual mass

Indexed keywords

BLEOMYCIN; CD68 ANTIGEN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TISSUE SECTION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; ADOLESCENT; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HODGKIN DISEASE; MACROPHAGE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; TUMOR VOLUME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; COMBINED MODALITY THERAPY; FEMALE; HODGKIN DISEASE; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 84932133827     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.963081     Document Type: Article

References (38)

1. Swerdlow SH, Campo E, Harris NL. WHO classif cation of tumours of haematopoietic and lymphoid tissue. Lyon: IARC; 2008.
2. Montalbán C, García JF, Abraira V, et al. Inf uence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol 2004;22: 1664-1673.
3. Diehl V, Stein H, Hummel M, et al. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program 2003:225-247.
4. Josting A, Ruefer U, Franklin J, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000;96:1280-1286.
5. Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011; 117: 1806-1816.
6. Ansell SM. Hodgkin lymphoma: 2012 update on diagnosis, risk-stratifcation, and management. Am J Hematol 2012;87:1096-1103.
7. Borchmann P, Haverkamp H, Diehl V, et al. Eight cyclesofescalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: f nal analysis of the HD12 Trial of the German Hodgkin Study Group. J Clin Oncol 2011;29:4234-4242.
8. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-652.
9. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-1514.
10. Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 1989;73:47-56.
11. Diehl V, Stein H, Hummel M, et al. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology 2003;2003:225-247.
12. Townsend W, Linch D. Hodgkin's lymphoma in adults. Lancet 2012;380:836-847.
13. Hutchings M. How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma? Hematology Am Soc Hematol Educ Program 2012:322-327.
14. Colonna P, Jais JP, Desablens B, et al. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. J Clin Oncol 1996;14:1928-1935.
15. Cheson BD, Pfstner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
16. Weihrauch MR, Manzke O, Beyer M, et al. Elevated serum levels of CC T ymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res 2005;65:5516-5519.
17. Plattel WJ, van den Berg A, Visser L, et al. Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma. Haematologica 2012;97:410-415.
18. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362: 875-885.
19. Liu Y, Sattarzadeh A, Diepstra A, et al. The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component. Semin Cancer Biol 2014;24:15-22.
20. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124: 263-266.
21. Normann SJ. Macrophage inf ltration and tumor progression. Cancer Metastasis Rev 1985; 4: 277-291.
22. Tzankov A, Matter MS, Dirnhofer S. Ref ned prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiol J Immunopathol Mol Cell Biol 2010;77:301-308.
23. Azambuja D, Natkunam Y, Biasoli I, et al. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol 2012;23:736-742.
24. Kamper P, Bendix K, Hamilton-Dutoit S, et al. Tumor-inf ltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011; 96:269-276.
25. Yoon DH, Koh YW, Kang HJ, et al. CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Haematol 2012;88:292-305.
26. Santoro A, Bonadonna G. Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Cancer Chemother Pharmacol 1979;2:101-105.
27. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395.
28. Horning SJ, Williams J, Bartlett NL, et al. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 2000;18:972-980.
29. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011;29:1812-1826.
30. Aldinucci D, Gloghini A, Pinto A, et al. Te classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010;221:248-263.
31. Diehl V. Hematology. Are macrophages the bad guys in Hodgkin lymphoma? Nat Rev Clin Oncol 2010; 7: 301-302.
32. Kayal S, Mathur S, Karak AK, et al. CD68 tumor-associated macrophage marker is not prognostic of clinical outcome in classical Hodgkin lymphoma. Leuk Lymphoma 2014;55:1031-1037.
33. Petrausch U, Samaras P, Veit-Haibach P, et al. Hodgkin's lymphoma in remission after f rst-line therapy: which patients need FDG-PET/CT for follow-up? Ann Oncol 2010;21:1053-1057.
34. Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, et al. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma 2011; 52:1913-1919.
35. Panico L, Ronconi F, Lepore M, et al. Prognostic role of tumor-associated macrophages and angiogenesis in classical Hodgkin lymphoma. Leuk Lymphoma 2013;54:2418-2425.
36. Tan KL, Scott DW, Hong F, et al. Tumor-associated macrophages predict inferior outcomes in classical Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 2012;120:3280-3287.
37. Zaki MAA, Wada N, Ikeda J, et al. Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma. Virchows Arch Int J Pathol 2011;459:361-366.
38. Sanchez-Espiridion B, Martin-Moreno AM, Montalban C, et al. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin lymphoma. Haematologica 2012;97:1080-1084.